RESUMO
Norovirus (NoV) are the most common cause of acute gastroenteritidis in humans worldwide. They are transmitted through consumption of contaminated food, or mostly by direct person-to-person contact. However, susceptibility to NoV infection is variable. NoVs recognize carbohydrate ligand, including A, B, H and Lewis histoblood group antigen (HBGAs) for attachment to human epithelial cells. Synthesis of these HBGAs requires various glycosyltransferase encoded by the ABO, FUT2, FUT3 genes. The presence of distinct carbohydrates structures dependent upon the combined polymorphism at the FUT2, FUT3 and ABO loci influences susceptibility to NoV infection. NoV-glycan interactions studies show that different strains recognize specific HBGAs. Together with herd immunity, HBGAs play a major role in the epidemiology and evolution of NoVs.
Assuntos
Infecções por Caliciviridae/genética , Gastroenterite/genética , Predisposição Genética para Doença , Norovirus , Sistema ABO de Grupos Sanguíneos/genética , Sistema ABO de Grupos Sanguíneos/imunologia , Animais , Antígenos de Grupos Sanguíneos/genética , Antígenos de Grupos Sanguíneos/imunologia , Infecções por Caliciviridae/imunologia , Gastroenterite/imunologia , Gastroenterite/virologia , Humanos , Antígenos do Grupo Sanguíneo de Lewis/genética , Antígenos do Grupo Sanguíneo de Lewis/imunologia , Modelos Biológicos , Modelos Moleculares , Norovirus/química , Norovirus/genética , Norovirus/imunologia , Norovirus/fisiologiaRESUMO
Antigens of the ABH and Lewis histo-blood group family have been known for a long time. Yet their biological meaning is still largely obscure. Based on the available knowledge about the genes involved in their biosynthesis and about their tissue distribution in humans and other mammals, we discuss here the selective forces that may maintain or propagate these oligosaccharide antigens. The ABO, alpha 1,2fucosyltransferase and alpha 1,3fucosyltransferase enzyme families have been generated by gene duplications. Members of these families contribute to biosynthesis of the antigens through epistatic interactions. We suggest that the highly polymorphic genes of each family provide intraspecies diversity that allows coping with diverse and rapidly evolving pathogens. In contrast, the genes of low frequency polymorphism are expected to play roles at the cellular level, although they may be dispensable at the individual level. In addition, some members of these three gene families are expected to be functionally redundant and may either provide a reservoir for additional diversity in the future or become inactivated. We also discuss the role of the ABH and Lewis histo-blood group antigens in pathologies such as cancer and cardiovascular diseases, but argue that it is merely incidental and devoid of evolutionary impact.
Assuntos
Sistema ABO de Grupos Sanguíneos/genética , Glicosiltransferases/metabolismo , Antígenos do Grupo Sanguíneo de Lewis/genética , Oligossacarídeos/genética , Sistema ABO de Grupos Sanguíneos/biossíntese , Sistema ABO de Grupos Sanguíneos/química , Animais , Doenças Cardiovasculares/sangue , Epistasia Genética , Evolução Molecular , Frequência do Gene , Variação Genética , Humanos , Antígenos do Grupo Sanguíneo de Lewis/biossíntese , Antígenos do Grupo Sanguíneo de Lewis/química , Modelos Biológicos , Neoplasias/sangue , Oligossacarídeos/química , Polimorfismo Genético , Distribuição TecidualRESUMO
This study examined and compared the minimal inhibition concentrations (MICs) of enrofloxacin against 393 Staphylococcus intermedius strains isolated in France from canine pyodermas during three different years, 1995 (174 isolates), 1997 (101 isolates) and 1999 (118 isolates). The MICs of enrofloxacin against these strains ranged from 0.063 to 64 mg L-1, with MIC50 and MIC90 equal to 0.125 and 0.25 mg L-1, respectively. Two resistant strains were found, but only among isolates collected in 1999. The data show that resistance to enrofloxacin among S. intermedius strains is still rare in dogs, but the selection in vitro of variants in which the MICs were increased 4-16-fold after 10 serial passages in subinhibitory concentrations of enrofloxacin suggests that inappropriate use might favour the development of resistant strains in vivo.
Assuntos
Anti-Infecciosos/farmacologia , Doenças do Cão/tratamento farmacológico , Fluoroquinolonas , Pioderma/veterinária , Quinolonas/farmacologia , Infecções Estafilocócicas/veterinária , Staphylococcus/efeitos dos fármacos , Animais , Anti-Infecciosos/uso terapêutico , Cães , Resistência Microbiana a Medicamentos , Enrofloxacina , Testes de Sensibilidade Microbiana , Pioderma/tratamento farmacológico , Quinolonas/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Staphylococcus/classificaçãoRESUMO
The post-antibiotic effect in vitro (PAE) of cephalexin was determined according to a broth dilution method against 5 isolates of Staphylococcus intermedius obtained from cases of canine pyoderma. Two durations of exposure and 3 concentrations were tested. The PAE increased when time of exposure or concentration increased. The mean PAE ranged from 0.7 to 3.3 h. The PAE of cephalexin against Staph-ylococcus intermedius may be clinically relevant when selecting a dosage regimen to treat pyoderma in dogs.
RESUMO
A polyclonal antibody was raised against the Galalpha1-3Gal carbohydrate epitope, which is expressed by all mammals (except man and the closest primate species) by immunizing hens with rabbit erythrocyte membranes. IgY was isolated from egg yolks, and affinity-purified on a Galalpha1-3Gal-Synsorb column. Two percent of the initial IgY fraction was recovered. The specificity of the affinity-purified antibody was characterized by: absorption with human, rabbit and pig erythrocytes; by using Synsorb columns; by inhibition with different saccharides; and by immunostaining of glycolipids separated on thin layer chromatograms. A weak reactivity was found toward blood group B or blood group Pk determinant, depending on the assay system used. Such reactivities were abolished after absorption by the appropriate sorbents, yielding a polyclonal anti-Galalpha1-3Gal antibody with narrow specificity.
